Importantly, the treatment of RKO cells expressing high endogenous levels of NPM1 with the inhibitor of the PI3K/AKT pathway significantly enhanced cell sensitivity to 5-fluorouracil, which suggests that AKT signalling participates in regulating the oncogenic and anti-apoptotic effects of NPM1 expression that reduce the efficacy of chemotherapy in BRAF mutant colon cancer. The gene discussed is AKT1; the disease is colonic neoplasm.